Adjuvant Trastuzumab Emtansine Plus Trastuzumab Improved Disease-Free, Overall Survival in HER2+ Early Breast Cancer
Combination therapy with trastuzumab emtansine and trastuzumab significantly enhances survival rates in HER2-positive early breast cancer, outperforming trastuzumab alone.